LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL
Clinical trials for LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL explained in plain language.
Never miss a new study
Get alerted when new LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL trials appear
Sign up with your email to follow new studies for LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Blood cancer drug safety tracked over 5 years
Disease control OngoingThis study looks at the long-term safety of the drug pirtobrutinib in people with certain blood cancers, like chronic lymphocytic leukemia or non-Hodgkin lymphoma. It is for those who completed an earlier study and are still benefiting from the treatment. Participants will receiv…
Matched conditions: LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL
Phase: PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated May 17, 2026 02:08 UTC
-
New CLL strategy: only add extra drug if cancer persists
Disease control OngoingThis study tests a personalized approach for people with chronic lymphocytic leukemia (CLL). Instead of giving everyone three drugs from the start, participants first receive two oral medications (zanubrutinib and venetoclax). Only those who still have detectable cancer cells aft…
Matched conditions: LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL
Phase: PHASE2 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated May 17, 2026 02:06 UTC
-
New pill combo shows promise in battling blood cancer
Disease control OngoingThis phase 3 study tests whether a combination of two targeted drugs, ibrutinib and venetoclax, works better than the current standard therapy for adults with chronic lymphocytic leukemia (CLL) who are older or have other health issues. About 211 participants will receive either …
Matched conditions: LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New pill shows promise in battling advanced blood cancers
Disease control OngoingThis early-stage study tests an experimental pill called LOXO-338 in people with advanced blood cancers (like certain leukemias, lymphomas, and multiple myeloma) who have already tried standard treatments. The main goals are to find the safest dose and to see if the drug can shri…
Matched conditions: LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated May 12, 2026 13:51 UTC
-
New antibody therapy targets Hard-to-Treat blood cancers
Disease control OngoingThis early-stage study tests an experimental drug, JNJ-80948543, that helps the body's immune T-cells attack cancer cells. It is for people with certain types of blood cancer (non-Hodgkin lymphoma or chronic lymphocytic leukemia) that have not responded to other treatments. The m…
Matched conditions: LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL
Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated May 11, 2026 20:39 UTC
-
Cancer patients monitored for Long-Term side effects in safety study
Knowledge-focused ENROLLING_BY_INVITATIONThis study follows people with different cancers who have already received treatment in an earlier study. The main goal is to track serious side effects and other health issues over time. No new treatment is given; participants are simply monitored for safety.
Matched conditions: LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL
Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Knowledge-focused
Last updated May 15, 2026 11:57 UTC